| 产品描述: | Varespladib methyl (A-002; LY333013) 是一种选择性的磷脂酶 A2 (PLA2) 抑制剂。 |
| 靶点: |
phospholipase A2 (PLA2);Phospholipase |
| 体外研究: |
Varespladib methyl (LY333013) is an orally-administered methyl ester pro-drug that is metabolized to LY315920. Varespladib and its orally bioavailable prodrug, Varespladib methyl (methyl-Varespladib) shows high-level secretory PLA2 (sPLA2) inhibition at nanomolar and picomolar concentrations against 28 medically important snake venoms from six continents. |
| 参考文献: |
1. Bradley JD, et al. A randomized, double-blinded, placebo-controlled clinical trial of LY333013, a selective inhibitor of group II secretory phospholipase A2, in the treatment of rheumatoid arthritis. J Rheumatol. 2005 Mar;32(3):417-23. 2. Lewin M, et al. Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation. Toxins (Basel). 2016 Aug 25;8(9). pii: E248. |
| 溶解性: |
soluble in DMSO |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.535 ml |
12.677 ml |
25.354 ml |
| 5 mM |
0.507 ml |
2.535 ml |
5.071 ml |
| 10 mM |
0.254 ml |
1.268 ml |
2.535 ml |
| 50 mM |
0.051 ml |
0.254 ml |
0.507 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |